TERAVOLT: Thoracic Cancers International COVID-19 Collaboration. Cancer cell Whisenant, J. G., Trama, A., Torri, V., De Toma, A., Viscardi, G., Cortellini, A., Micheilin, O., Barlesi, F., Dingemans, A. C., Van Meerbeeck, J., Pancaldi, V., Soo, R. A., Leighl, N. B., Peters, S., Wakelee, H., Garassino, M. C., Horn, L. 2020


Prior publications on small subsets of cancer patients infected with SARS CoV-2 have shown an increased risk of mortality compared to the general population. Furthermore, patients with thoracic malignancies are thought to be at particularly high risk given their older age, smoking habits, and pre-existing cardio-pulmonary comorbidities. For this reason, physicians around the world have formed TERAVOLT, a global consortium dedicated to understanding the impact of COVID-19 on patients with thoracic malignancies.

View details for DOI 10.1016/j.ccell.2020.05.008

View details for PubMedID 32425702